Table 1.
Baseline demographics, clinical characteristics, and treatment details by randomised group.
| No IGRT N = 46 n (%) |
IGRT – S N = 129 n (%) |
IGRT – R N = 101 n (%) |
Main CHHiP trial N = 3216 n (%) |
|
|---|---|---|---|---|
| Age at registration (years) | ||||
| Median (IQR) | 70 (66–73) | 72 (66–75) | 71 (67–75) | 69 (44–85) |
| T stage (clinical assessment) | ||||
| T1 | 14 (30) | 41 (32) | 40 (40) | 1170 (36) |
| T2 | 27 (59) | 80 (62) | 54 (53) | 1766 (55) |
| T3 | 5 (11) | 8 (6) | 7 (7) | 277 (9) |
| PSA (pre-hormone treatment) (ng/ml) | ||||
| Median (IQR) | 9.5 (6.6–13.8) | 9.6 (6.5–12.5) | 8 (6.8–11.3) | 10 (7–15) |
| NCCN Risk group | ||||
| Low | 2 (4) | 13 (10) | 17 (17) | 484 (15) |
| Medium | 36 (78) | 104 (81) | 75 (74) | 2347 (73) |
| High | 8 (17) | 12 (9) | 9 (9) | 385 (12) |
| CHHiP treatment allocation | ||||
| 74 Gy/37 Fr | 16 (35) | 41 (32) | 30 (29) | 1065 (33) |
| 60 Gy/20 Fr | 15 (32.5) | 45 (35) | 35 (35) | 1074 (33) |
| 57 Gy/19 Fr | 15 (32.5) | 43 (33) | 36 (36) | 1077 (34) |
| Hormone therapy | ||||
| None | 1 (2) | 3 (2) | 4 (4) | 90 (3) |
| Bicalutamide monotherapy | 6 (13) | 29 (23) | 21 (21) | 403 (13) |
| LHRH agonist | 39 (85) | 96 (74) | 74 (73) | 2700 (83) |
| Unknown | 0 (0) | 1 (1) | 2 (2) | 9 (<1) |
| Duration of hormone therapy | ||||
| Median (IQR) in days | 107 (94–161) | 145 (112–178) | 147 (121–161) | 168 (133–196) |
| Diabetes | ||||
| Yes | 6 (13) | 14 (11) | 10 (10) | 342 (11) |
| No | 40 (87) | 107 (83) | 83 (82) | NA |
| Unknown | 8 (6) | 8 (8) | NA | |
| Hypertension | ||||
| Yes | 20 (43) | 53 (41) | 33 (33) | 1276 (40) |
| No | 25 (54) | 68 (53) | 60 (59) | NA |
| Unknown | 1 (2) | 8 (6) | 8 (8) | NA |
NCCN: National Comprehensive Cancer Network.